Understanding vaccine safety information from the vaccine adverse event reporting system

被引:292
|
作者
Varricchio, F [1 ]
Iskander, J
Destefano, F
Ball, R
Pless, R
Braun, MM
Chen, RT
机构
[1] Food & Drug Adm, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Ottawa, ON, Canada
[2] CDCP, Natl Immunizat Program, Epidemiol & Surveillance Div, Immunizat Safety Branch, Ottawa, ON, Canada
[3] Hlth Canada, Ctr Infect Dis Prevent & Control, Immunizat & Resp Infect Div, Immunizat Safety Unit, Ottawa, ON K1A 0L2, Canada
关键词
adverse event; vaccine; vaccine adverse event reporting system (VAERS);
D O I
10.1097/00006454-200404000-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [11] Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016
    Su, John R.
    Moro, Pedro L.
    Ng, Carmen S.
    Lewis, Paige W.
    Said, Maria A.
    Cano, Maria V.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (04) : 1465 - 1473
  • [12] Adverse events after Fluzone® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013
    Moro, Pedro L.
    Harrington, Theresa
    Shimabukuro, Tom
    Cano, Maria
    Museru, Oidda I.
    Menschik, David
    Broder, Karen
    VACCINE, 2013, 31 (43) : 4984 - 4987
  • [13] Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018
    Su, John R.
    McNeil, Michael M.
    Welsh, Kerry J.
    Marquez, Paige L.
    Ng, Carmen
    Yan, Ming
    Cano, Maria, V
    VACCINE, 2021, 39 (05) : 839 - 845
  • [14] Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017
    Bonaldo, Giulia
    Vaccheri, Alberto
    D'Annibali, Ottavio
    Motola, Domenico
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (03) : 634 - 643
  • [15] Advanced Clinical Decision Support for Vaccine Adverse Event Detection and Reporting
    Baker, Meghan A.
    Kaelber, David C.
    Bar-Shain, David S.
    Moro, Pedro L.
    Zambarano, Bob
    Mazza, Megan
    Garcia, Crystal
    Henry, Adam
    Platt, Richard
    Klompas, Michael
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) : 864 - 870
  • [16] COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS)
    Zhang, Bing
    Yu, Xiao
    Liu, Jinxing
    Liu, Jinbao
    Liu, Pengfei
    BMC WOMENS HEALTH, 2022, 22 (01)
  • [17] Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024)
    Woo, Emily Jane
    Miller, Elaine R.
    Stroud, Erin
    VACCINE, 2024, 42 (24)
  • [18] Death and Disability Reported with Cases of Vaccine Anaphylaxis Stratified by Administration Setting: An Analysis of the Vaccine Adverse Event Reporting System from 2017 to 2022
    Klosko, Rachel C.
    Lynch, Sarah E.
    Cabral, Danielle L.
    Nagaraju, Kanneboyina
    Johnston, Yvonne A.
    Steinberg, Joshua D.
    McCall, Kenneth L.
    VACCINES, 2023, 11 (02)
  • [19] Allergic Reactions After Egg-Free Recombinant Influenza Vaccine: Reports to the US Vaccine Adverse Event Reporting System
    Woo, Emily Jane
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (05) : 777 - 780
  • [20] Thrombocytopenia after vaccination: Case reports to the US Vaccine Adverse Event Reporting System, 1990-2008
    Woo, Emily Jane
    Wise, Robert P.
    Menschik, David
    Shadomy, Sean V.
    Iskander, John
    Beeler, Judy
    Varricchio, Frederick
    Ball, Robert
    VACCINE, 2011, 29 (06) : 1319 - 1323